Skip to content

Transcutaneous Electrical Acupoint Stimulation (TEAS) on Postoperative Urinary Retention After Radical Surgery for Cervical Cancer: A Prospective Randomized Controlled Trial

Transcutaneous Electrical Acupoint Stimulation on Postoperative Urinary Retention After Radical Surgery for Cervical Cancer: A Prospective Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002091
Enrollment
Unknown
Registered
2025-10-28
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative urinary retention

Interventions

Treatment Group (TEAS Group):TEAS Intervention
Control Group (Sham TEAS Group):Sham TEAS Intervention

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age range of 18-70 years, expected survival period = 6 months; (2)Meets diagnostic criteria, with an indwelling catheter duration of more than 14 days but less than 1 year; (3) No history of urinary system diseases before surgery; (4) Clear consciousness, unobstructed communication, daily living ability, patients or family members can learn the TEAS operation; (5) No serious systemic diseases such as heart, liver, brain, kidney, etc. (6) Karnofsky functional status score (KPS) = 70 points; (7) Voluntarily participate and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: (1) Obstructive urinary retention, such as urethral stricture or stones; (2)combined with other serious systemic diseases, advanced cachexia; (3)Patients with pacemaker implantation or metal implantation in the body; (4)The treatment site has skin lesions or is not suitable for TEAS treatment in other populations; (5) Physical or mental disorders with cognitive impairment; (6) Other clinical trial participants who are currently involved in affecting the results of this study; (7) Those who do not agree to participate in clinical trials; (8) The evaluator has determined that the participant is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Residual urine volume of bladder;

Secondary

MeasureTime frame
The proportion of participants who removed the urinary catheter;Patient Quality of Life Evaluation Scale(EQRTC QLQ-C30);The proportion of patients who have a urinary tract infection;

Countries

China

Contacts

Public ContactChao Lu

Zhejiang Cancer Hospital

luchao@zjcc.org.cn15869128904

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026